Cargando…
Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study
BACKGROUND: Programmed death‐1 (PD‐1) blocking antibodies have been shown to improve progression‐free survival (PFS) and overall survival in a subset of patients with non–small cell lung cancer (NSCLC). However, the objective response rate with these agents remains low, and the vast majority of NSCL...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812069/ https://www.ncbi.nlm.nih.gov/pubmed/33150733 http://dx.doi.org/10.1111/1759-7714.13731 |
_version_ | 1783637590223618048 |
---|---|
author | Han, Ying Mu, Di Liu, Ting Zhang, Huan Zhang, Jiali Li, Shuzhan Wang, Rui Du, Weijiao Hui, Zhenzhen Zhang, Xinwei Ren, Xiubao |
author_facet | Han, Ying Mu, Di Liu, Ting Zhang, Huan Zhang, Jiali Li, Shuzhan Wang, Rui Du, Weijiao Hui, Zhenzhen Zhang, Xinwei Ren, Xiubao |
author_sort | Han, Ying |
collection | PubMed |
description | BACKGROUND: Programmed death‐1 (PD‐1) blocking antibodies have been shown to improve progression‐free survival (PFS) and overall survival in a subset of patients with non–small cell lung cancer (NSCLC). However, the objective response rate with these agents remains low, and the vast majority of NSCLC patients require alternative combination treatment regimens to prolong their survival. The purpose of this study was to evaluate the clinical efficacy of autologous cytokine‐induced killer (CIK) cell infusions combined with PD‐1 blocking antibodies in patients with NSCLC. METHODS: In this preliminary study, we investigated the safety and immune function effectiveness of PD‐1 blockade antibodies pembrolizumab or nivolumab administered in combination with or without autologous CIK cell infusions in 18 patients with advanced NSCLC. The peripheral blood mononuclear cells were isolated from these patients and the expression level of some cell surface molecules like PD‐1 were detected using flow cytometry to reflect the effectiveness of this combination regimen. RESULTS: No treatment‐related deaths occurred in either cohort. In comparison with the pretreatment level, CD3(+)CD56(+)CD16(+) T cells were significantly increased with the combination therapy, while myeloid‐derived suppressor cells were significantly increased with PD‐1 blocking antibody therapy alone but not with combination therapy. Although the serum interleukin‐4 level was downregulated following treatment with the combination regimen, interferon‐γ levels were unchanged. CONCLUSIONS: The purpose of this clinical study was to report the clinical efficacy and lack of exacerbated autoimmune adverse events with a combination of PD‐1 blockade and CIK cell infusions in patients with advanced NSCLC, further supporting assessments of this combination in future clinical trials. |
format | Online Article Text |
id | pubmed-7812069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-78120692021-01-22 Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study Han, Ying Mu, Di Liu, Ting Zhang, Huan Zhang, Jiali Li, Shuzhan Wang, Rui Du, Weijiao Hui, Zhenzhen Zhang, Xinwei Ren, Xiubao Thorac Cancer Original Articles BACKGROUND: Programmed death‐1 (PD‐1) blocking antibodies have been shown to improve progression‐free survival (PFS) and overall survival in a subset of patients with non–small cell lung cancer (NSCLC). However, the objective response rate with these agents remains low, and the vast majority of NSCLC patients require alternative combination treatment regimens to prolong their survival. The purpose of this study was to evaluate the clinical efficacy of autologous cytokine‐induced killer (CIK) cell infusions combined with PD‐1 blocking antibodies in patients with NSCLC. METHODS: In this preliminary study, we investigated the safety and immune function effectiveness of PD‐1 blockade antibodies pembrolizumab or nivolumab administered in combination with or without autologous CIK cell infusions in 18 patients with advanced NSCLC. The peripheral blood mononuclear cells were isolated from these patients and the expression level of some cell surface molecules like PD‐1 were detected using flow cytometry to reflect the effectiveness of this combination regimen. RESULTS: No treatment‐related deaths occurred in either cohort. In comparison with the pretreatment level, CD3(+)CD56(+)CD16(+) T cells were significantly increased with the combination therapy, while myeloid‐derived suppressor cells were significantly increased with PD‐1 blocking antibody therapy alone but not with combination therapy. Although the serum interleukin‐4 level was downregulated following treatment with the combination regimen, interferon‐γ levels were unchanged. CONCLUSIONS: The purpose of this clinical study was to report the clinical efficacy and lack of exacerbated autoimmune adverse events with a combination of PD‐1 blockade and CIK cell infusions in patients with advanced NSCLC, further supporting assessments of this combination in future clinical trials. John Wiley & Sons Australia, Ltd 2020-11-04 2021-01 /pmc/articles/PMC7812069/ /pubmed/33150733 http://dx.doi.org/10.1111/1759-7714.13731 Text en © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Han, Ying Mu, Di Liu, Ting Zhang, Huan Zhang, Jiali Li, Shuzhan Wang, Rui Du, Weijiao Hui, Zhenzhen Zhang, Xinwei Ren, Xiubao Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study |
title | Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study |
title_full | Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study |
title_fullStr | Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study |
title_full_unstemmed | Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study |
title_short | Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study |
title_sort | autologous cytokine‐induced killer (cik) cells enhance the clinical response to pd‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: a preliminary study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812069/ https://www.ncbi.nlm.nih.gov/pubmed/33150733 http://dx.doi.org/10.1111/1759-7714.13731 |
work_keys_str_mv | AT hanying autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy AT mudi autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy AT liuting autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy AT zhanghuan autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy AT zhangjiali autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy AT lishuzhan autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy AT wangrui autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy AT duweijiao autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy AT huizhenzhen autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy AT zhangxinwei autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy AT renxiubao autologouscytokineinducedkillercikcellsenhancetheclinicalresponsetopd1blockingantibodiesinpatientswithadvancednonsmallcelllungcancerapreliminarystudy |